nach oben

Current Bladder Dysfunction Reports

Erschienen in:

28.03.2017 | BPH-Related Voiding Dysfunction (R Lee, Section Editor)

Urinary Biomarkers for Bladder Outlet Obstruction

verfasst von: Katia Monastyrskaya, Fiona C. Burkhard

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Lower urinary tract symptoms (LUTS) in elderly men are often caused by bladder outlet obstruction (BOO) as a result of benign prostatic hyperplasia (BPH). The consequences of BOO-induced LUTS include the low compliance high pressure bladder as well as the high volume low pressure bladder with loss of bladder function.

Recent Findings

Timely diagnosis of BOO may help prevent bladder decompensation and preserve organ contractility. In this review, we will discuss the latest developments in the quest for reliable urinary biomarkers of BPH-induced benign prostatic obstruction (BPO). We will summarise the possible mechanisms of BOO-induced bladder remodelling and their implications for the diagnosis and therapy of BOO-induced LUTS.

Summary

A number potential of urinary biomarkers and non-invasive tests have been proposed for BOO, but do not seem to have enough specificity and sensitivity. Combinations of proteins, miRNAs and small molecules need to be evaluated to increase the reliability and discriminative potential of biomarkers.

Hypolite JA, Chang S, Zheng Y, DiSanto ME, Zderic SA, Wein AJ, et al. Partial bladder outlet obstruction induces urethral smooth muscle hypertrophy and decreased force generation. J Urol. 2006;175(2):777–82. doi:10.1016/s0022-5347(05)00138-2.CrossRefPubMed

Myers JB, Dall’era JE, Koul S, Kumar B, Khandrika L, Flynn BJ, et al. Biochemical alterations in partial bladder outlet obstruction in mice: up-regulation of the mitogen activated protein kinase pathway. J Urol. 2009;181(4):1926–31. doi:10.1016/j.juro.2008.11.077.CrossRefPubMed

Chacko S, Chang S, Hypolite J, DiSanto M, Wein A. Alteration of contractile and regulatory proteins following partial bladder outlet obstruction. ScandJUrolNephrolSuppl. 2004;215:26–36.

Metcalfe PD, Wang J, Jiao H, Huang Y, Hori K, Moore RB, et al. Bladder outlet obstruction: progression from inflammation to fibrosis. BJU Int. 2010;106(11):1686–94. doi:10.1111/j.1464-410X.2010.09445.x.CrossRefPubMed

Atkinson Jr AJ. J, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95. doi:10.1067/mcp.2001.113989.

•• Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099–109. doi:10.1016/j.eururo.2014.12.038. A broader approach to the assessment of male LUTS; contains a practical algorithm for diagnostic evaluation. CrossRefPubMed

Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn. 2003;22(2):105–8. doi:10.1002/nau.10099.CrossRefPubMed

Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Hofner K. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol. 2008;54(2):419–26. doi:10.1016/j.eururo.2008.02.017.CrossRefPubMed

Oh MM, Choi H, Park MG, Kang SH, Cheon J, Bae JH, et al. Is there a correlation between the presence of idiopathic detrusor overactivity and the degree of bladder outlet obstruction? Urology. 2011;77(1):167–70. doi:10.1016/j.urology.2010.05.034.CrossRefPubMed

10.

•• Malde S, Nambiar AK, Umbach R, Lam TB, Bach T, Bachmann A, et al. Systematic review of the performance of noninvasive tests in diagnosing bladder outlet obstruction in men with lower urinary tract symptoms. Eur Urol. 2016; doi:10.1016/j.eururo.2016.09.026. A systematic review of the diagnostic accuracy of noninvasive tests in diagnosing BOO in men with lower urinary tract symptoms (LUTS) using a pressure-flow study as the reference standard. PubMed

11.

Kim M, Cheeti A, Yoo C, Choo M, Paick JS, Oh SJ. Non-invasive clinical parameters for the prediction of urodynamic bladder outlet obstruction: analysis using causal Bayesian networks. PLoS One. 2014;9(11):e113131. doi:10.1371/journal.pone.0113131.CrossRefPubMedPubMedCentral

12.

Fry CH, Sahai A, Vahabi B, Kanai AJ, Birder LA. What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):602–5. doi:10.1002/nau.22558.CrossRefPubMed

13.

Phanish MK, Wahab NA, Hendry BM, Dockrell ME. TGF-beta1-induced connective tissue growth factor (CCN2) expression in human renal proximal tubule epithelial cells requires Ras/MEK/ERK and Smad signalling. Nephron Exp Nephrol. 2005;100(4):e156–65. doi:10.1159/000085445.CrossRefPubMed

14.

Song YS, Lee HJ, Doo SW, An J, Kim SU. Enhanced angiogenesis and relaxation of bladder as early response to bladder outlet obstruction. Int J Urol. 2013;20(1):116–22. doi:10.1111/j.1442-2042.2012.03217.x.CrossRefPubMed

15.

•• Koeck I, Burkhard FC, Monastyrskaya K. Activation of common signaling pathways during remodeling of the heart and the bladder. Biochem Pharmacol. 2016;102:7–19. doi:10.1016/j.bcp.2015.09.012. This review summarizes the current knowledge of molecular alterations in the heart and the bladder and highlights common signaling pathways and regulatory events. CrossRefPubMed

16.

Lu M, Zhang Q, Deng M, Miao J, Guo Y, Gao W, et al. An analysis of human microRNA and disease associations. PLoS One. 2008;3(10):e3420. doi:10.1371/journal.pone.0003420.CrossRefPubMedPubMedCentral

17.

Wilmott JS, Zhang XD, Hersey P, Scolyer RA. The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology. 2011;43(6):657–71. doi:10.1097/PAT.0b013e32834a7358.CrossRefPubMed

18.

Duan LJ, Qi J, Kong XJ, Huang T, Qian XQ, Xu D, et al. miR-133 modulates TGF-beta 1-induced bladder smooth muscle cell hypertrophic and fibrotic response: implication for a role of microRNA in bladder wall remodeling caused by bladder outlet obstruction. Cell Signal. 2015;27(2):215–27. doi:10.1016/j.cellsig.2014.11.001.CrossRefPubMed

19.

Ekman M, Bhattachariya A, Dahan D, Uvelius B, Albinsson S, Sward K. Mir-29 repression in bladder outlet obstruction contributes to matrix remodeling and altered stiffness. PLoS One. 2013;8(12):e82308. doi:10.1371/journal.pone.0082308.CrossRefPubMedPubMedCentral

20.

Sadegh MK, Ekman M, Krawczyk K, Svensson D, Goransson O, Dahan D, et al. Detrusor induction of miR-132/212 following bladder outlet obstruction: association with MeCP2 repression and cell viability. PLoS One. 2015;10(1):e0116784. doi:10.1371/journal.pone.0116784.CrossRefPubMedPubMedCentral

21.

Gheinani AH, Burkhard FC, Monastyrskaya K. Deciphering microRNA code in pain and inflammation: lessons from bladder pain syndrome. Cell Mol Life Sci. 2013;70(20):3773–89. doi:10.1007/s00018-013-1275-7.CrossRefPubMed

22.

Sanchez Freire V, Burkhard FC, Kessler TM, Kuhn A, Draeger A, Monastyrskaya K. MicroRNAs may mediate the down-regulation of neurokinin-1 receptor in chronic bladder pain syndrome. Am J Pathol. 2010;176(1):288–303. doi:10.2353/ajpath.2010.090552.CrossRefPubMedPubMedCentral

23.

Hashemi Gheinani A, Burkhard FC, Rehrauer H, Aquino Fournier C, Monastyrskaya K. MicroRNA MiR-199a-5p regulates smooth muscle cell proliferation and morphology by targeting WNT2 signaling pathway. J Biol Chem. 2015;290(11):7067–86. doi:10.1074/jbc.M114.618694.CrossRefPubMedPubMedCentral

24.

Monastyrskaya K, Sanchez-Freire V, Hashemi Gheinani A, Klumpp DJ, Babiychuk EB, Draeger A, et al. miR-199a-5p regulates urothelial permeability and may play a role in bladder pain syndrome. Am J Pathol. 2013;182(2):431–48. doi:10.1016/j.ajpath.2012.10.020.CrossRefPubMed

25.

Zhang S, Lv JW, Yang P, Yu Q, Pang J, Wang Z, et al. Loss of dicer exacerbates cyclophosphamide-induced bladder overactivity by enhancing purinergic signaling. Am J Pathol. 2012;181(3):937–46. doi:10.1016/j.ajpath.2012.05.035.CrossRefPubMed

26.

Ekman M, Albinsson S, Uvelius B, Sward K. MicroRNAs in bladder outlet obstruction: relationship to growth and matrix remodelling. Basic & clinical pharmacology & toxicology. 2016;119(Suppl 3):5–17. doi:10.1111/bcpt.12534.CrossRef

27.

•• Gheinani AH, Kiss B, Moltzahn F, Keller I, Bruggmann R, Rehrauer H, et al. Characterization of miRNA-regulated networks, hubs of signaling, and biomarkers in obstruction-induced bladder dysfunction. JCI insight. 2017;2(2):e89560. doi:10.1172/jci.insight.89560. A comprehensive transcriptome analysis of BOO-induced bladder remodelling in humans. CrossRefPubMedPubMedCentral

28.

Wood SL, Knowles MA, Thompson D, Selby PJ, Banks RE. Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nature reviews Urology. 2013;10(4):206–18. doi:10.1038/nrurol.2013.24.CrossRefPubMed

29.

Vanmassenhove J, Vanholder R, Nagler E, Van Biesen W. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2013;28(2):254–73. doi:10.1093/ndt/gfs380.CrossRef

30.

Altobelli E, Angeletti PM, Latella G. Role of urinary biomarkers in the diagnosis of adenoma and colorectal cancer: a systematic review and meta-analysis. J Cancer. 2016;7(14):1984–2004. doi:10.7150/jca.16244.CrossRefPubMedPubMedCentral

31.

D’Costa JJ, Goldsmith JC, Wilson JS, Bryan RT, Ward DG. A systematic review of the diagnostic and prognostic value of urinary protein biomarkers in urothelial bladder cancer. Bladder cancer (Amsterdam, Netherlands). 2016;2(3):301–17. doi:10.3233/blc-160054.CrossRefPubMedCentral

32.

McGrath S, Christidis D, Perera M, Hong SK, Manning T, Vela I, et al. Prostate cancer biomarkers: are we hitting the mark? Prostate international. 2016;4(4):130–5. doi:10.1016/j.prnil.2016.07.002.CrossRefPubMedPubMedCentral

33.

An M, Gao Y. Urinary biomarkers of brain diseases. Genomics, proteomics & bioinformatics. 2015;13(6):345–54. doi:10.1016/j.gpb.2015.08.005.CrossRef

34.

Burns JA, Kreder KJ, Lubaroff DM, See WA. Alterations in constituent urinary proteins in response to bladder outlet obstruction in rats. J Urol. 1998;159(5):1747–51. doi:10.1097/00005392-199805000-00105.CrossRefPubMed

35.

Bowen T, Jenkins RH, Fraser DJ. MicroRNAs, transforming growth factor beta-1, and tissue fibrosis. J Pathol. 2013;229(2):274–85. doi:10.1002/path.4119.CrossRefPubMed

36.

Meng XM, Chung AC, Lan HY. Role of the TGF-beta/BMP-7/Smad pathways in renal diseases. Clin Sci (Lond). 2013;124(4):243–54. doi:10.1042/cs20120252.CrossRef

37.

Wang WJ, Qu XQ, Yu XM, Lv W, Yu HY. Analysis of the expression of HMGB-1, CXCL16, miRNA-30a, and TGF-beta1 in primary nephritic syndrome patients and its significance. Genet Mol Res. 2015;14(3):9841–8. doi:10.4238/2015.August.19.17.CrossRefPubMed

38.

De Muro P, Faedda R, Fresu P, Masala A, Cigni A, Concas G, et al. Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacol Res. 2004;49(3):293–8.CrossRefPubMed

39.

Tsapenko MV, Nwoko RE, Borland TM, Voskoboev NV, Pflueger A, Rule AD, et al. Measurement of urinary TGF-beta1 in patients with diabetes mellitus and normal controls. Clin Biochem. 2013;46(15):1430–5. doi:10.1016/j.clinbiochem.2013.05.041.CrossRefPubMed

40.

Chul Kim J, Il Seo S, Hyun Park Y, Kon Hwang TA. Changes in detrusor and urinary growth factors according to detrusor function after partial bladder outlet obstruction in the rat. Urology. 2001;57(2):371–5.CrossRefPubMed

41.

Shi B, Zhu Y, Laudon V, Ran L, Liu Y, Xu Z. Alterations of urine TGF-beta1 and bFGF following bladder outlet obstruction: a predictor for detrusor contractibility? Urol Int. 2009;82(1):43–7. doi:10.1159/000176024.CrossRefPubMed

42.

Monga M, Gabal-Shehab LL, Stein P. Urinary transforming growth factor-beta1 levels correlate with bladder outlet obstruction. Int J Urol. 2001;8(9):487–9.CrossRefPubMed

43.

Mitterberger M, Pallwein L, Gradl J, Frauscher F, Neuwirt H, Leunhartsberger N, et al. Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. BJU Int. 2007;99(4):831–5. doi:10.1111/j.1464-410X.2006.06735.x.CrossRefPubMed

44.

de Jongh R, Dambros M, Haenen GR, den Hartog GJ, Bast A, van Kerrebroeck PE, et al. Partial bladder outlet obstruction reduces the tissue antioxidant capacity and muscle nerve density of the guinea pig bladder. Neurourol Urodyn. 2009;28(5):461–7. doi:10.1002/nau.20677.CrossRefPubMed

45.

Lin WY, Chen CS, Wu SB, Lin YP, Levin RM, Wei YH. Oxidative stress biomarkers in urine and plasma of rabbits with partial bladder outlet obstruction. BJU Int. 2011;107(11):1839–43. doi:10.1111/j.1464-410X.2010.09597.x.CrossRefPubMed

46.

Lin WY, Wu SB, Lin YP, Chang PJ, Levin RM, Wei YH. Reversing bladder outlet obstruction attenuates systemic and tissue oxidative stress. BJU Int. 2012;110(8):1208–13. doi:10.1111/j.1464-410X.2012.11185.x.CrossRefPubMed

47.

Clayton DB, Stephany HA, Ching CB, Rahman SA, Tanaka ST, Thomas JC, et al. F2-isoprostanes as a biomarker of oxidative stress in the mouse bladder. J Urol. 2014;191(5 Suppl):1597–601. doi:10.1016/j.juro.2013.09.027.CrossRefPubMed

48.

Fowke JH, Koyama T, Fadare O, Clark PE. Does inflammation mediate the obesity and BPH relationship? An epidemiologic analysis of body composition and inflammatory markers in blood, urine, and prostate tissue, and the relationship with prostate enlargement and lower urinary tract symptoms. PLoS One. 2016;11(6):e0156918. doi:10.1371/journal.pone.0156918.CrossRefPubMedPubMedCentral

49.

Kim JC, Park EY, Hong SH, Seo SI, Park YH, Hwang TK. Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Int J Urol. 2005;12(10):875–80. doi:10.1111/j.1442-2042.2005.01140.x.CrossRefPubMed

50.

Ghoniem G, Faruqui N, Elmissiry M, Mahdy A, Abdelwahab H, Oommen M, et al. Differential profile analysis of urinary cytokines in patients with overactive bladder. Int Urogynecol J. 2011;22(8):953–61. doi:10.1007/s00192-011-1401-8.CrossRefPubMed

51.

Lin WY, Hsieh CC, Yang TY, Chen ML, Huang LY, Lin YP, et al. Transient increase in circulating myeloid-derived suppressor cells after partial bladder outlet obstruction. J Urol. 2014;192(5):1569–73. doi:10.1016/j.juro.2014.05.045.CrossRefPubMed

52.

Anukam KC, Hayes K, Summers K, Reid G. Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 may help downregulate TNF-Alpha, IL-6, IL-8, IL-10 and IL-12 (p70) in the neurogenic bladder of spinal cord injured patient with urinary tract infections: a two-case study. Advances in urology. 2009:680363. doi:10.1155/2009/680363.

53.

Birder LA. Urinary bladder urothelium: molecular sensors of chemical/thermal/mechanical stimuli. Vasc Pharmacol. 2006;45(4):221–6. doi:10.1016/j.vph.2005.08.027.CrossRef

54.

Wang EC, Lee JM, Ruiz WG, Balestreire EM, von Bodungen M, Barrick S, et al. ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells. J Clin Invest. 2005;115(9):2412–22. doi:10.1172/jci24086.CrossRefPubMedPubMedCentral

55.

Cheng Y, Mansfield KJ, Allen W, Millard RJ, Burcher E, Moore KH. Correlation between cystometric volumes, ATP release, and pH in women with overactive bladder versus controls. Neurourol Urodyn. 2013;32(7):969–73. doi:10.1002/nau.22344.CrossRefPubMed

56.

Silva-Ramos M, Silva I, Oliveira O, Ferreira S, Reis MJ, Oliveira JC, et al. Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome. PLoS One. 2013;8(5):e64696. doi:10.1371/journal.pone.0064696.CrossRefPubMedPubMedCentral

57.

•• Silva-Ramos M, Silva I, Oliveira JC, Correia-de-Sa P. Increased urinary adenosine triphosphate in patients with bladder outlet obstruction due to benign prostate hyperplasia. Prostate. 2016;76(15):1353–63. doi:10.1002/pros.23207. Evidence that urinary ATP can be a high-sensitive non-invasive biomarker of BOO, which may have a discriminative value of detrusor competence when comparing BPH patients with low urinary flow rates. CrossRefPubMed

58.

•• Cruz CD. Neurotrophins in bladder function: what do we know and where do we go from here? Neurourol Urodyn. 2014;33(1):39–45. doi:10.1002/nau.22438. In depth review of knowledge about the importance of NTs in bladder function will be reviewed, with a focus on the most well-studied NTs, nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF). CrossRefPubMed

59.

Steers WD, Kolbeck S, Creedon D, Tuttle JB. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest. 1991;88(5):1709–15. doi:10.1172/jci115488.CrossRefPubMedPubMedCentral

60.

Persson K, Steers WD, Tuttle JB. Regulation of nerve growth factor secretion in smooth muscle cells cultured from rat bladder body, base and urethra. J Urol. 1997;157(5):2000–6.CrossRefPubMed

61.

Coelho A, Wolf-Johnston AS, Shinde S, Cruz CD, Cruz F, Avelino A, et al. Urinary bladder inflammation induces changes in urothelial nerve growth factor and TRPV1 channels. Br J Pharmacol. 2015;172(7):1691–9. doi:10.1111/bph.12958.CrossRefPubMedPubMedCentral

62.

Ochodnicky P, Cruz CD, Yoshimura N, Michel MC. Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn. 2011;30(7):1227–41. doi:10.1002/nau.21022.PubMed

63.

Seth JH, Sahai A, Khan MS, van der Aa F, de Ridder D, Panicker JN, et al. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)? BJU Int. 2013;111(3):372–80. doi:10.1111/j.1464-410X.2012.11672.x.CrossRefPubMed

64.

•• Cruz CD, Coelho A, Antunes-Lopes T, Cruz F. Biomarkers of spinal cord injury and ensuing bladder dysfunction. Adv Drug Deliv Rev. 2015;82–83:153–9. doi:10.1016/j.addr.2014.11.007. Reviews the latest studies of structural neuronal and glial proteins, inflammatory proteins and neuroimaging methods; explores urinary biomarkers of the functional changes that typically affect bladder function.

65.

Kuo HC, Liu HT, Chancellor MB. Can urinary nerve growth factor be a biomarker for overactive bladder? Reviews in urology. 2010;12(2–3):e69–77.PubMedPubMedCentral

66.

Rachaneni S, Arya P, Latthe P. Urinary nerve growth factor: a biomarker of detrusor overactivity? A systematic review. Int Urogynecol J. 2013;24(10):1603–9. doi:10.1007/s00192-013-2104-0.CrossRefPubMed

67.

Liu HT, Kuo HC. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology. 2008;72(1):104–8. discussion 8 doi:10.1016/j.urology.2008.01.069.CrossRefPubMed

68.

Wada N, Matsumoto S, Kita M, Hashizume K, Kakizaki H. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride. Int J Urol. 2014;21(12):1258–62. doi:10.1111/iju.12570.CrossRefPubMed

69.

Chan R, Munoz A, Wenker EP, Stewart J, Boone T, Khavari R. The association of urinary nerve growth factor levels with bladder outlet obstruction in women. Female Pelvic Med Reconstr Surg. 2015;21(2):111–5. doi:10.1097/spv.0000000000000126.CrossRefPubMedPubMedCentral

70.

Merighi A, Salio C, Ghirri A, Lossi L, Ferrini F, Betelli C, et al. BDNF as a pain modulator. Prog Neurobiol. 2008;85(3):297–317. doi:10.1016/j.pneurobio.2008.04.004.CrossRefPubMed

71.

Lommatzsch M, Braun A, Mannsfeldt A, Botchkarev VA, Botchkareva NV, Paus R, et al. Abundant production of brain-derived neurotrophic factor by adult visceral epithelia: implications for paracrine and target-derived neurotrophic functions. Am J Pathol. 1999;155(4):1183–93. doi:10.1016/s0002-9440(10)65221-2.CrossRefPubMedPubMedCentral

72.

West AE, Pruunsild P, Timmusk T. Neurotrophins: transcription and translation. Handb Exp Pharmacol. 2014;220:67–100. doi:10.1007/978-3-642-45106-5_4.CrossRefPubMed

73.

Oddiah D, Anand P, McMahon SB, Rattray M. Rapid increase of NGF, BDNF and NT-3 mRNAs in inflamed bladder. Neuroreport. 1998;9(7):1455–8.CrossRefPubMed

74.

Qiao LY, Shen S, Liu M, Xia C, Kay JC, Zhang QL. Inflammation and activity augment brain-derived neurotrophic factor peripheral release. Neuroscience. 2016;318:114–21. doi:10.1016/j.neuroscience.2016.01.018.CrossRefPubMedPubMedCentral

75.

Frias B, Santos J, Morgado M, Sousa MM, Gray SM, McCloskey KD, et al. The role of brain-derived neurotrophic factor (BDNF) in the development of neurogenic detrusor overactivity (NDO). J Neurosci. 2015;35(5):2146–60. doi:10.1523/jneurosci.0373-14.2015.CrossRefPubMedPubMedCentral

76.

Antunes-Lopes T, Pinto R, Barros SC, Botelho F, Silva CM, Cruz CD, et al. Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol. 2013;189(1):359–65. doi:10.1016/j.juro.2012.08.187.CrossRefPubMed

77.

Qiao LY, Yu SJ, Kay JC, Xia CM. In vivo regulation of brain-derived neurotrophic factor in dorsal root ganglia is mediated by nerve growth factor-triggered Akt activation during cystitis. PLoS One. 2013;8(11):e81547. doi:10.1371/journal.pone.0081547.CrossRefPubMedPubMedCentral

78.

Zvara P, Kliment Jr J, DeRoss AL, Irwin BH, Malley SE, Plante MK, et al. Differential expression of bladder neurotrophic factor mRNA in male and female rats after bladder outflow obstruction. J Urol. 2002;168(6):2682–8. doi:10.1097/01.ju.0000037426.21468.5b.CrossRefPubMed

79.

Girard BM, Malley SE, Vizzard MA. Neurotrophin/receptor expression in urinary bladder of mice with overexpression of NGF in urothelium. Am J Physiol Renal Physiol. 2011;300(2):F345–55. doi:10.1152/ajprenal.00515.2010.CrossRefPubMed

80.

Jang H, Han DS, Yuk SM. Changes of neuregulin-1 (NRG-1) expression in a rat model of overactive bladder induced by partial urethral obstruction: is NRG-1 a new biomarker of overactive bladder? BMC Urol. 2013;13:54. doi:10.1186/1471-2490-13-54.CrossRefPubMedPubMedCentral

81.

Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–83. doi:10.1083/jcb.201211138.CrossRefPubMedPubMedCentral

82.

Ajit SK. Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules. Sensors (Basel). 2012;12(3):3359–69. doi:10.3390/s120303359.CrossRef

83.

Cortez MA, Welsh JW, Calin GA. Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res. 2012;195:151–61. doi:10.1007/978-3-642-28160-0_13.CrossRefPubMed

84.

Redis RS, Calin S, Yang Y, You MJ, Calin GA. Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol Ther. 2012;136(2):169–74. doi:10.1016/j.pharmthera.2012.08.003.CrossRefPubMed

85.

Lee YS, Pressman S, Andress AP, Kim K, White JL, Cassidy JJ, et al. Silencing by small RNAs is linked to endosomal trafficking. Nat Cell Biol. 2009;11(9):1150–6. doi:10.1038/ncb1930.CrossRefPubMedPubMedCentral

Titel: Urinary Biomarkers for Bladder Outlet Obstruction
verfasst von: Katia Monastyrskaya
Fiona C. Burkhard
Publikationsdatum: 28.03.2017
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 2/2017
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-017-0418-3

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Urinary Biomarkers for Bladder Outlet Obstruction

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Urologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Darf man die Behandlung eines Neonazis ablehnen?

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Urologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Meditate Temporary Implantable Nitinol Device

Neuromodulation in the Treatment of Voiding Dysfunction and Fecal Incontinence in Male and Female Cancer Survivors

Urinary Diversion for Incontinence and Voiding Dysfunction in Cancer Survivors: a Critical Review of the Literature

Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms

The Artificial Urinary Sphincter: Evolution and Implementation of New Techniques in the Man with Stress Incontinence After Treatment for Prostate Cancer

Accurate Estimation of Prostate Size in the Evaluation of Nocturia

Neu im Fachgebiet Urologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Darf man die Behandlung eines Neonazis ablehnen?

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Urologie